Adjuvant EGFR-Targeted Therapy as a Game Changer in Multimodal NSCLC Management

1 Views
Published
Chair & Presenter, David R. Jones, MD, and Nathan A. Pennell, MD, PhD, FASCO, discuss NSCLC in this CME/MOC activity titled “Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC information, and to apply for credit, please visit us at PeerView.com/MHD865. CME/MOC credit will be available until December 2, 2022.
Category
Management
Be the first to comment